Today, several biopharmaceutical firms are taking their therapies to the clinical study phase, so the stakes are high. Many of these evolving firms have spent years to focus exclusively on developing their therapies, where the clinical trial phase can seem daunting. A clinical trial is only done when a new test or treatment may improve the care of patients. It is conducted to amass data regarding the safety and efficacy of a new drug and device development.
This is where companies like Veristat come in. Veristat is a full-service clinical research organization (CRO) that offers clinical development services and expertise for this critical next step. The company relies on its solid record of running thorough, efficient and well-planned studies to make it stand tall among the competition.
The Business Challenge
As a CRO, Veristat applies its 25 years of clinical and regulatory expertise across multiple medical disciplines, including oncology, neurology, infectious diseases, cardiology and respiratory, with considerable expertise in rare diseases.
However, to strengthen best practices and offer biopharmaceutical firms customized and flexible clinical development expertise, Veristat sought an instinctive clinical research platform with a wide range of capabilities.
The Solution: Veristat Relies on IBM Clinical Development Platform
To ease its challenges, Veristat deployed the IBM® Clinical Development platform and relies on it as one of its preferred electronic data capture (EDC) platforms. The IBM® Clinical Development solution armed Veristat with a powerful clinical research platform, provides fully integrated advanced modules, such as medical coding and randomization.
Before deploying the medical coding module, Veristat typically did the coding in a separate coding tool. That meant exporting data from the EDC system, applying the medical codes, and then integrating the coded dictionary values back into the raw data.
However, with the new module, the coded values are already a part of the raw data. According to Veristat, it has streamlined a lot of its processes, especially downstream because the company no longer needs help from the programming group to get the coded terms back into its extracts manually. Also, medical coding makes study data more accessible while the trial is ongoing.
Eventually, IBM’s advanced modules helped Veristat continue to simplify clinical study processes and increase overall trial efficiency.
After deploying IBM solutions including randomization, supply management, medical coding and lab normal range processes, Veristat has seen increased study efficiency to bring therapies to the market more quickly. That also opened the ways for more hands-on project oversight and strategic consulting, which ultimately enhances the partnership between Veristat and its customers.
Veristat also considers the control it retains over the EDC solution to be an important component of its success. Moreover, the IBM Clinical Development platform also helps Veristat to strengthen its reputation as a knowledgeable and capable CRO.